Recognizing that the challenges facing Taiwan’s pharmaceutical market are inextricably linked to the structure and soundess of the overall healthcare system, the board of the International Reasearch-based Pharmaceutical Manufacturers Association (IRPMA) last year decided to prepare a comprehensive set of recommendations for shaping the next generation of Taiwan’s healthcare. The Association commissioned consultancy PwC Taiwan…

“Robust intellectual property (IP) protection is vital for biopharmaceutical innovation,” stresses a recently released report from Geneva Network, a UK-based public policy research and advocacy organization specializing in international intellectual property, health, and trade issues. The report – written by Geneva Network researcher Jack Ellis, a former Asia-Pacific editor of Intellectual Asset Management magazine –…

Cigna Corporation has been providing life and supplemental health insurance – and peace of mind – to consumers in Taiwan for the past 27 years. Now Cigna is exploring opportunities to expand beyond insurance to provide health and wellness services in Taiwan leveraging Cigna Corporation’s global health expertise and best practices in other markets around…

Shire_hemophilia

Patients with rare congenital and chronic catastrophic diseases are often debilitated and impoverished by their conditions. These diseases are generally little known, even to physicians, and patients in the U.S. and EU suffer for an average of five to seven years before being accurately diagnosed. Even after diagnosis, effective treatment is frequently unavailable. The low…

Last October in this space, in an editorial entitled “A Significant Initiative,” AmCham Taipei hailed the Taiwan government’s decision to extend the notice-and-comment period for proposed new or revised regulations. Previously a mere 14 days, hardly enough time for stakeholders to absorb the content of the proposed new measures and to formulate a comprehensive response,…